Format

Send to

Choose Destination
Blood. 2014 Jul 17;124(3):385-92. doi: 10.1182/blood-2014-04-566737. Epub 2014 May 23.

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.

Author information

1
University of Texas Southwestern Medical Center, Dallas, TX;
2
Baylor Scott & White Health, Temple, TX;
3
The University of Texas MD Anderson Cancer Center, Houston, TX;
4
Stanford University School of Medicine, Stanford, CA;
5
Cleveland Clinic Taussig Cancer Institute, Cleveland, OH;
6
Northwestern University Feinberg School of Medicine, Chicago, IL;
7
City of Hope, Duarte, CA;
8
Bon Secours St. Francis Health Systems, Greenville, SC;
9
EFS Bourgogne Franche-Comte, INSERM UMR1098, EFS Bourgogne Franche-Comte, Besancon, France; and.
10
Stemline Therapeutics, Inc., New York, NY.

Abstract

This is the first prospective study of treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic malignancy derived from plasmacytoid dendritic cells that typically involves the skin and rapidly progresses to a leukemia phase. Despite being initially responsive to intensive combination chemotherapy, most patients relapse and succumb to their disease. Because BPDCN blasts overexpress the interleukin-3 receptor (IL3R), the activity of SL-401, diptheria toxin (DT)388IL3 composed of the catalytic and translocation domains of DT fused to IL3, was evaluated in BPDCN patients in a phase 1-2 study. Eleven patients were treated with a single course of SL-401 at 12.5 μg/kg intravenously over 15 minutes daily for up to 5 doses; 3 patients who had initial responses to SL-401 received a second course in relapse. The most common adverse events including fever, chills, hypotension, edema, hypoalbuminemia, thrombocytopenia, and transaminasemia were transient. Seven of 9 evaluable (78%) BPDCN patients had major responses including 5 complete responses and 2 partial responses after a single course of SL-401. The median duration of responses was 5 months (range, 1-20+ months). Further studies of SL-401 in BPDCN including those involving multiple sequential courses, alternate schedules, and combinations with other therapeutics are warranted. This trial is registered at clinicaltrials.gov as #NCT00397579.

PMID:
24859366
PMCID:
PMC4260361
DOI:
10.1182/blood-2014-04-566737
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center